SH3RF2 Silencing Enhances Ovarian Cancer Cell Apoptosis and Cisplatin Sensitivity via RBPMS/AP-1 Axis Inhibition

This study investigates the mechanism by which silencing SH3RF2 promotes apoptosis in ovarian cancer cells and increases sensitivity to cisplatin chemotherapy through negative regulation of the RBPMS/AP-1 axis. The research reveals that silencing SH3RF2 negatively regulates the RBPMS/AP-1 axis, leading to enhanced cell death and increased chemotherapeutic efficacy.